276 related articles for article (PubMed ID: 37996401)
1. New drugs targeting calcitonin gene-related peptide for the management of migraines.
Tana C; Cipollone F; Giamberardino MA; Martelletti P
Expert Opin Emerg Drugs; 2023 Dec; 28(4):233-240. PubMed ID: 37996401
[TBL] [Abstract][Full Text] [Related]
2. CGRP monoclonal antibodies and CGRP receptor antagonists (Gepants) in migraine prevention.
Caronna E; Alpuente A; Torres-Ferrus M; Pozo-Rosich P
Handb Clin Neurol; 2024; 199():107-124. PubMed ID: 38307640
[TBL] [Abstract][Full Text] [Related]
3. Recent advances in targeting calcitonin gene-related peptide for the treatment of menstrual migraine: A narrative review.
Jiang Y; Huang ZL
Medicine (Baltimore); 2022 Jun; 101(24):e29361. PubMed ID: 35713436
[TBL] [Abstract][Full Text] [Related]
4. Emerging drugs for the preventive treatment of migraine: a review of CGRP monoclonal antibodies and gepants trials.
Silvestro M; Orologio I; Siciliano M; Trojsi F; Tessitore A; Tedeschi G; Russo A
Expert Opin Emerg Drugs; 2023 Dec; 28(2):79-96. PubMed ID: 37185047
[TBL] [Abstract][Full Text] [Related]
5. CGRP-targeted medication in chronic migraine - systematic review.
Oliveira R; Gil-Gouveia R; Puledda F
J Headache Pain; 2024 Apr; 25(1):51. PubMed ID: 38575868
[TBL] [Abstract][Full Text] [Related]
6. Targeting CGRP for the Prevention of Migraine and Cluster Headache: A Narrative Review.
Yuan H; Spare NM; Silberstein SD
Headache; 2019 Jul; 59 Suppl 2():20-32. PubMed ID: 31291020
[TBL] [Abstract][Full Text] [Related]
7. CGRP and Migraine: The Role of Blocking Calcitonin Gene-Related Peptide Ligand and Receptor in the Management of Migraine.
Maasumi K; Michael RL; Rapoport AM
Drugs; 2018 Jun; 78(9):913-928. PubMed ID: 29869205
[TBL] [Abstract][Full Text] [Related]
8. Calcitonin gene-related peptide (CGRP)-targeted therapies as preventive and acute treatments for migraine-The monoclonal antibodies and gepants.
Chiang CC; Schwedt TJ
Prog Brain Res; 2020; 255():143-170. PubMed ID: 33008505
[TBL] [Abstract][Full Text] [Related]
9. History and Review of anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: From Translational Research to Treatment.
Tepper SJ
Headache; 2018 Nov; 58 Suppl 3():238-275. PubMed ID: 30242830
[TBL] [Abstract][Full Text] [Related]
10. Calcitonin Gene-Related Peptide (CGRP)-Targeted Monoclonal Antibodies and Antagonists in Migraine: Current Evidence and Rationale.
Cohen F; Yuan H; Silberstein SD
BioDrugs; 2022 May; 36(3):341-358. PubMed ID: 35476215
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of outcomes of calcitonin gene-related peptide (CGRP)-targeting therapies for acute and preventive migraine treatment based on patient sex.
Porreca F; Navratilova E; Hirman J; van den Brink AM; Lipton RB; Dodick DW
Cephalalgia; 2024 Mar; 44(3):3331024241238153. PubMed ID: 38477313
[TBL] [Abstract][Full Text] [Related]
12. Anti-CGRP and anti-CGRP receptor monoclonal antibodies as antimigraine agents. Potential differences in safety profile postulated on a pathophysiological basis.
Tringali G; Navarra P
Peptides; 2019 Jun; 116():16-21. PubMed ID: 31018157
[TBL] [Abstract][Full Text] [Related]
13. Calcitonin gene-related peptide-targeting drugs for migraine: how pharmacology might inform treatment decisions.
Al-Hassany L; Goadsby PJ; Danser AHJ; MaassenVanDenBrink A
Lancet Neurol; 2022 Mar; 21(3):284-294. PubMed ID: 35093196
[TBL] [Abstract][Full Text] [Related]
14. Future prophylactic treatments in migraine: Beyond anti-CGRP monoclonal antibodies and gepants.
Do TP; Al-Saoudi A; Ashina M
Rev Neurol (Paris); 2021 Sep; 177(7):827-833. PubMed ID: 34294458
[TBL] [Abstract][Full Text] [Related]
15. Developments in targeting calcitonin gene-related peptide.
Alabbad S; Figueredo N; Yuan H; Silberstein S
Expert Rev Neurother; 2024 May; 24(5):477-485. PubMed ID: 38557226
[TBL] [Abstract][Full Text] [Related]
16. The pharmacotherapeutic management of episodic and chronic migraine with gepants.
Tajti J; Szok D; Csáti A; Vécsei L
Expert Opin Pharmacother; 2023 Jun; 24(8):947-958. PubMed ID: 37038933
[TBL] [Abstract][Full Text] [Related]
17. CGRP inhibitors for migraine prophylaxis: a safety review.
Rivera-Mancilla E; Villalón CM; MaassenVanDenBrink A
Expert Opin Drug Saf; 2020 Oct; 19(10):1237-1250. PubMed ID: 32811190
[TBL] [Abstract][Full Text] [Related]
18. Monoclonal antibodies blocking CGRP transmission: An update on their added value in migraine prevention.
Schoenen J; Manise M; Nonis R; Gérard P; Timmermans G
Rev Neurol (Paris); 2020 Dec; 176(10):788-803. PubMed ID: 32758365
[TBL] [Abstract][Full Text] [Related]
19. An observational study on monoclonal antibodies against calcitonin-gene-related peptide and its receptor.
Schiano di Cola F; Bolchini M; Ceccardi G; Caratozzolo S; Liberini P; Rao R; Padovani A
Eur J Neurol; 2023 Jun; 30(6):1764-1773. PubMed ID: 36856538
[TBL] [Abstract][Full Text] [Related]
20. Calcitonin gene-related peptide in migraine: from pathophysiology to treatment.
Santos-Lasaosa S; Belvís R; Cuadrado ML; Díaz-Insa S; Gago-Veiga A; Guerrero-Peral AL; Huerta M; Irimia P; Láinez JM; Latorre G; Leira R; Pascual J; Porta-Etessam J; Sánchez Del Río M; Viguera J; Pozo-Rosich P
Neurologia (Engl Ed); 2022 Jun; 37(5):390-402. PubMed ID: 35672126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
